1271727-90-2

Basic information

• Product Name: C₅₁H₈₂ClFN₃O₄⁽¹⁺⁾*Cl^(1-)
• CAS NO: 1271727-90-2
• Molecular Weight: 891.134
• Mol File: 1271727-90-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: C₅₁H₈₂ClFN₃O₄⁽¹⁺⁾*Cl^(1-)(CAS DataBase Reference)
• NIST Chemistry Reference: C₅₁H₈₂ClFN₃O₄⁽¹⁺⁾*Cl^(1-)(1271727-90-2)
• EPA Substance Registry System: C₅₁H₈₂ClFN₃O₄⁽¹⁺⁾*Cl^(1-)(1271727-90-2)

Safety Data

• Hazardous Substances Data: 1271727-90-2(Hazardous Substances Data)

Upstream product

• 143-15-7 1-dodecylbromide 
• 52-86-8 haloperidol 
• 1271727-75-3 tert-butyl 2-(didodecylamino)acetate 
• 853994-07-7 C₂₉H₃₆ClFN₂O₅ 
• 853994-08-8 C₂₄H₂₈ClFN₂O₃ 

Relevant articles and documents

Structure-activity study to develop cationic lipid-conjugated haloperidol derivatives as a new class of anticancer therapeutics

Haloperidol (HP), a neuroleptic drug, shows high affinity toward-receptors (SR). HP and reduced-HP at higher concentration were known to induce apoptosis in SR-overexpressing carcinomas and melanomas. Herein, we report the development of cationic lipid-conjugated haloperidol as a new class of anticancer therapeutics. In comparison to HP, the C-8 carbon chain analogue (HP-C8) showed significantly high, SR-assisted antiproliferative activity against cancer cells via caspase-3-mediated apoptosis and down-regulation of pAkt. Moreover, melanoma tumor aggressiveness in HP-C8-treated mice was significantly lower than that in HP-treated mice. HP-C8 simultaneously reduced Akt-protein level and increased Bax/Bcl-2 ratio in vascular endothelial cells, thereby indicating a possible protein kinase down-regulatory and apoptosis inducing role in tumor-associated vascular cells. In conclusion, we developed-receptor-targeting cationic lipid-modified HP derivatives as a promising class of anticancer therapeutic that concurrently affects cancer and tumor environment associated angiogenic vascular cells through induction of apoptosis and Akt protein down-regulation.